Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Q3 net loss widens to $127.5 million on lower collaboration revenue

Negative Impact 3 of 5 earnings Written later

Intellia Therapeutics reported third-quarter 2026 results, with collaboration revenue of $7.2 million, down from $13.8 million a year earlier, and a net loss of $127.5 million, up from $101.3 million. The company said cash, cash equivalents and marketable securities were $614.8 million at September 30, 2026, and that existing resources should fund operations at least into 2028.

Key points

  • Collaboration revenue fell to $7.2 million from $13.8 million, mainly due to lower Regeneron revenue.
  • Net loss was $127.5 million, including a $10.4 million unrealized loss from changes in investment fair value.
  • Cash and marketable securities were $614.8 million at September 30, 2026, which the company expects to fund operations at least into 2028.
  • FDA set a PDUFA target action date of March 10, 2027 for lonvo-z in HAE.

The filing

CompanyIntellia Therapeutics, Inc. (NTLA)
Form8-K, current report
Filed with the SECNov 5, 2026, 8:15 AM ET
Accession number0001193125-26-448673

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.